Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
25 sept. 2024 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an...
Keiretsu Forum Investor Capital Expo: A Must-Attend Event for Angel Investors, Family Offices, and Venture Capital Professionals
25 sept. 2024 07h22 HE
|
Keiretsu Forum Mid-Atlantic
The upcoming event offers a rare opportunity for accredited investors to engage directly with early-stage portfolio companies with a completed DD package.
Nectero Medical Recognized as a 2024 AZBio Fast Lane Award Winner
24 sept. 2024 08h00 HE
|
Nectero Medical
TEMPE, Ariz., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, announced today that it received a...
Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
24 sept. 2024 07h30 HE
|
Cytokinetics, Incorporated
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is November 4th, 2024 SOUTH SAN...
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
24 sept. 2024 07h30 HE
|
Ocugen
MALVERN, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
24 sept. 2024 07h00 HE
|
Can-Fite BioPharma Ltd.
The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE...
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
24 sept. 2024 06h00 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Life Sciences Week 2024: Advancing Innovation, Investment, and Collaboration in Alberta’s Life Sciences Sector
23 sept. 2024 13h10 HE
|
Applied Pharmaceutical Innovation (API)
Life Sciences Week, Alberta’s flagship event for showcasing the life sciences sector returns from September 23 to 27, 2024.
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
23 sept. 2024 08h00 HE
|
Assembly Biosciences, Inc.
– ABI-5366 was well-tolerated, with a favorable safety profile observed with exposure of up to 70 days – – Half-life of approximately 20 days supports once-weekly or once-monthly oral dosing; both...
Human Augmentation Market - Forecasts from 2024 to 2029: Advances in AI, Biotechnology, Nanotechnology, Robotics, and Materials Science Fueling Developments
23 sept. 2024 07h26 HE
|
Research and Markets
Dublin, Sept. 23, 2024 (GLOBE NEWSWIRE) -- The "Human Augmentation Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering.The human augmentation market is...